Cytek Biosciences, Inc.
CTKB
$4.81
$0.153.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 206.71M | 204.17M | 201.49M | 196.83M | 196.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 206.71M | 204.17M | 201.49M | 196.83M | 196.04M |
| Cost of Revenue | 99.48M | 98.61M | 97.03M | 91.60M | 89.35M |
| Gross Profit | 107.23M | 105.56M | 104.46M | 105.23M | 106.68M |
| SG&A Expenses | 117.42M | 113.08M | 108.38M | 99.80M | 95.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 254.16M | 248.04M | 241.88M | 228.63M | 222.90M |
| Operating Income | -47.45M | -43.87M | -40.39M | -31.81M | -26.86M |
| Income Before Tax | -40.82M | -35.95M | -29.84M | -15.49M | -7.56M |
| Income Tax Expenses | 39.76M | 38.06M | 36.70M | -2.67M | -1.16M |
| Earnings from Continuing Operations | -80.58 | -74.00 | -66.54 | -12.82 | -6.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.58M | -74.00M | -66.54M | -12.82M | -6.40M |
| EBIT | -47.45M | -43.87M | -40.39M | -31.81M | -26.86M |
| EBITDA | -39.76M | -36.30M | -32.81M | -24.27M | -19.39M |
| EPS Basic | -0.63 | -0.58 | -0.52 | -0.10 | -0.05 |
| Normalized Basic EPS | -0.20 | -0.18 | -0.15 | -0.08 | -0.04 |
| EPS Diluted | -0.63 | -0.58 | -0.52 | -0.11 | -0.06 |
| Normalized Diluted EPS | -0.20 | -0.18 | -0.15 | -0.08 | -0.04 |
| Average Basic Shares Outstanding | 513.88M | 511.35M | 510.99M | 511.90M | 515.36M |
| Average Diluted Shares Outstanding | 513.88M | 511.35M | 510.99M | 511.90M | 517.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |